AACR 2023: The RenMice HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets


In conclusion, the RenMice™ HiTS (Hyperimmune Target Specific) Platform enables accelerated identification of fully human antibodies with increased diversity of antibody paratopes and species cross-reactivity, using fully human antibody mice engineered to lack the target antigen. The RenMice™ HiTS Program is focusing on identifying more first-in-class drug targets across a range of therapeutic areas.